NCT03614949View on ClinicalTrials.gov

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

October 9, 2025

Study Completion Date

October 31, 2026

Conditions
Cervical CancerCervical Cancer RecurrentCervical Cancer Metastatic
Interventions
RADIATION

Stereotactic body radiation therapy (SBRT)

SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.

DRUG

Atezolizumab

Atezolizumab 1200 mg intravenously (IV) every 3 weeks.

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

43026

Ohio State University - OSUMC - Wexner Medical Center, Hilliard

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER